Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a β3-adrenoceptor agonist (Q42596957)

3 November 2017

title

Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a β3-adrenoceptor agonist (English)

1 reference

3 November 2017

Jennifer Lee

1

1 reference

3 November 2017

Selina Moy

2

1 reference

3 November 2017

John Meijer

3

1 reference

3 November 2017

Walter Krauwinkel

4

1 reference

3 November 2017

Taiji Sawamoto

5

1 reference

3 November 2017

Virginie Kerbusch

6

1 reference

3 November 2017

Donna Kowalski

7

1 reference

3 November 2017

Michael Roy

8

1 reference

3 November 2017

Alan Marion

9

1 reference

3 November 2017

Shin Takusagawa

10

1 reference

3 November 2017

Marcel van Gelderen

11

1 reference

3 November 2017

James Keirns

12

1 reference

3 November 2017

publication date

1 June 2013

1 reference

Clinical Drug Investigation

3 November 2017

published in

1 reference

3 November 2017

volume

33

1 reference

3 November 2017

issue

6

1 reference

3 November 2017

page(s)

429-440

1 reference

Effect of (R)-2-(2-aminothiazol-4-yl)-4'-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function

3 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0084-Y

An overview of the clinical use of antimuscarinics in the treatment of overactive bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0084-Y

Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0084-Y

Results of a randomized phase III trial of mirabegron in patients with overactive bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0084-Y

Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0084-Y

Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0084-Y

Homologous unequal cross-over involving a 2.8 kb direct repeat as a mechanism for the generation of allelic variants of human cytochrome P450 CYP2D6 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0084-Y

A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0084-Y

Development and validation of LC-MS/MS methods for the determination of mirabegron and its metabolites in human plasma and their application to a clinical pharmacokinetic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0084-Y

Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0084-Y

Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0084-Y

Drug-drug interaction mediated by inhibition and induction of P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0084-Y

Human drug metabolism and the cytochromes P450: application and relevance of in vitro models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0084-Y

Interaction of common azole antifungals with P glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0084-Y

Effects of ketoconazole on glucuronidation by UDP-glucuronosyltransferase enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0084-Y

Intestinal absorption mechanism of mirabegron, a potent and selective β₃-adrenoceptor agonist: involvement of human efflux and/or influx transport systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0084-Y

Effects of drug transporters on volume of distribution

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0084-Y

Pharmacokinetic interactions with rifampicin : clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0084-Y

Induction of cytochromes P450.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0084-Y

Comparison of inducibility of sulfotransferase and UDP-glucuronosyltransferase mRNAs by prototypical microsomal enzyme inducers in primary cultures of human and cynomolgus monkey hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0084-Y

Quantitative distribution of mRNAs encoding the 19 human UDP-glucuronosyltransferase enzymes in 26 adult and 3 fetal tissues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0084-Y

The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0084-Y

Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40261-013-0084-Y

Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes

21 January 2018

1 reference

12 December 2020

PCR-based genotyping for duplicated and deleted CYP2D6 genes

1 reference

12 December 2020

Cloning and sequencing of a new non-functional CYP2D6 allele: deletion of T1795 in exon 3 generates a premature stop codon

1 reference

12 December 2020

Rifampicin is only a weak inducer of CYP1A2-mediated presystemic and systemic metabolism: studies with tizanidine and caffeine

1 reference

12 December 2020

Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation

1 reference

12 December 2020

Inhibition of UDP-glucuronosyltransferase 2b7-catalyzed morphine glucuronidation by ketoconazole: dual mechanisms involving a novel noncompetitive mode

1 reference

12 December 2020

Rapid detection of CYP2D6 null alleles by long distance- and multiplex-polymerase chain reaction

1 reference

12 December 2020

The cytochrome P450 CYP2D6 allelic variant CYP2D6J and related polymorphisms in a European population

1 reference

12 December 2020

Proarrhythmic safety of repeat doses of mirabegron in healthy subjects: a randomized, double-blind, placebo-, and active-controlled thorough QT study

1 reference

12 December 2020

Ultrarapid drug metabolism: PCR-based detection of CYP2D6 gene duplication.

1 reference

12 December 2020

Evaluation of analytical and clinical performance of a dual-probe phenotyping method for CYP2D6 polymorphism and CYP3A4 activity screening

1 reference

12 December 2020

Ultrarapid metabolizers of debrisoquine: Characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene

1 reference

12 December 2020

Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism

1 reference

12 December 2020

Single dose pharmacokinetics and absolute bioavailability of mirabegron, a β₃-adrenoceptor agonist for treatment of overactive bladder

1 reference

12 December 2020

Identification of human cytochrome P450 isoforms and esterases involved in the metabolism of mirabegron, a potent and selective β3-adrenoceptor agonist

1 reference

12 December 2020

10.1007/S40261-013-0084-Y

Identifiers

DOI

1 reference

3 November 2017

1 reference